Just few of my observation from today... WOW ,
Post# of 148190
(Total Views: 500)
Posted On: 07/30/2019 9:01:18 PM
Just few of my observation from today...
WOW , I just finished listening , mostly twice... so much of information , and those doctors , really know what they talking about ,
Actually I didn't have to listen twice to Dr Lalezari , he is also clinician as I am , I understood him very well...
Dr Sacha is unbelievable what he can do with Leronlimab , and how many places we will go ,
True , until vaccination PrEP might be the best prevention .. and he is going to the most busy area with HIV in Asia...and about 25% of people high risk are not a good candidate for daily tablets ...
He feel possibly Laronlimab can be given for PrEP less often than once a week.
Different studies will be done not on our expense ... animal testing with primates , talking about cure ...
There is so much information in his part , he is working with Leronlimab for about 1 year now .
Need to listen again ...
Then Dr Lalezari
Talking first about TNBC ,
1. ) They going both ways , as Dr Cristofanelli want to get at least 5 treatment naive patients , little difficult ,
2. ) and with patients from Expended Access / Compassionate ,
- Prove of concept.
First patient from second group , going now with testing , if CCR5 positive will be injected very soon .
than talking about HIV...
13:15 - 14...
Response of patients with HIV to Leronlimab , probably longer overlap important ...
16:09 I am talking with potential partners , if in HIV we have 2 drug regiment , it will be a killer..
16:30 about monthly im injections , reality setting in...problems exist ...
And than Dr Patterson ,
Great , such a knowledge about CCR5 , this is why , imo , he developed Receptor Occupancy Test within few months ...
He discovered in 1990s connection of CCR5 to HIV ,
20:00 CCR5 highly regulated protein , maybe affected by infection , and other problems producing inflammation .....
21:30 there is no resistance with Leronlimab , but those condition can produce reduction of receptor occupancy ...
22 minutes ....But also he discovered one connection to cancers ....in immunology ..
CCR5 is expressed on the population of immune cells call T regulatory cells which inhibits response to cancers !!!!!
What a knowledge , I need to listen few more times to everything..
After 24:19 Dr NP answered some questions...
Meeting with FDA for pivotal mono Sept 20.
26....BLA, they negotiating all the time with FDA about 525 mg dose and CMC for combo.
They think it will be positive soon , and than entire BLA submitted by end of Sept.
I mill doll fee was waived by FDA .. I need to listen again why , but I am to tired already..
) I am not sure what time he said that...
Other things ,
they do go for meeting with FDA about prostate cancer August 28.
Dr Cristofannili with treatment naive breast cancer patients , think that with 5 patients doing better with Leronlimab then patients without for 4-5 months , he can ask for approval.
WOW , I just finished listening , mostly twice... so much of information , and those doctors , really know what they talking about ,
Actually I didn't have to listen twice to Dr Lalezari , he is also clinician as I am , I understood him very well...
Dr Sacha is unbelievable what he can do with Leronlimab , and how many places we will go ,
True , until vaccination PrEP might be the best prevention .. and he is going to the most busy area with HIV in Asia...and about 25% of people high risk are not a good candidate for daily tablets ...
He feel possibly Laronlimab can be given for PrEP less often than once a week.
Different studies will be done not on our expense ... animal testing with primates , talking about cure ...
There is so much information in his part , he is working with Leronlimab for about 1 year now .
Need to listen again ...
Then Dr Lalezari
Talking first about TNBC ,
1. ) They going both ways , as Dr Cristofanelli want to get at least 5 treatment naive patients , little difficult ,
2. ) and with patients from Expended Access / Compassionate ,
- Prove of concept.
First patient from second group , going now with testing , if CCR5 positive will be injected very soon .
than talking about HIV...
13:15 - 14...
Response of patients with HIV to Leronlimab , probably longer overlap important ...
16:09 I am talking with potential partners , if in HIV we have 2 drug regiment , it will be a killer..
16:30 about monthly im injections , reality setting in...problems exist ...
And than Dr Patterson ,
Great , such a knowledge about CCR5 , this is why , imo , he developed Receptor Occupancy Test within few months ...
He discovered in 1990s connection of CCR5 to HIV ,
20:00 CCR5 highly regulated protein , maybe affected by infection , and other problems producing inflammation .....
21:30 there is no resistance with Leronlimab , but those condition can produce reduction of receptor occupancy ...
22 minutes ....But also he discovered one connection to cancers ....in immunology ..
CCR5 is expressed on the population of immune cells call T regulatory cells which inhibits response to cancers !!!!!
What a knowledge , I need to listen few more times to everything..
After 24:19 Dr NP answered some questions...
Meeting with FDA for pivotal mono Sept 20.
26....BLA, they negotiating all the time with FDA about 525 mg dose and CMC for combo.
They think it will be positive soon , and than entire BLA submitted by end of Sept.
I mill doll fee was waived by FDA .. I need to listen again why , but I am to tired already..
) I am not sure what time he said that... Other things ,
they do go for meeting with FDA about prostate cancer August 28.
Dr Cristofannili with treatment naive breast cancer patients , think that with 5 patients doing better with Leronlimab then patients without for 4-5 months , he can ask for approval.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼